<DOC>
	<DOCNO>NCT00101634</DOCNO>
	<brief_summary>The purpose study determine efficacy ( well drug work ) , safety , side effect paliperidone palmitate compare placebo treatment symptom schizophrenia adult . The placebo use study nutritional substance know 20 % Intralipid emulsion give patient require intravenous feeding .</brief_summary>
	<brief_title>Efficacy Safety Long Acting Anti-Psychotic Versus Placebo Patients With Schizophrenia</brief_title>
	<detailed_description>Many patient schizophrenia difficulty adhere daily oral treatment regimen . Long-acting injectable ( LAI ) formulation may provide therapeutic plasma concentration several week , thereby eliminate need daily oral medication make compliance easy . This randomized ( patient assign different treatment group base solely chance ) , double-blind ( neither patient physician know placebo drug give dose ) , placebo-controlled , parallel group , multicenter , dose-response study adult schizophrenia . The study consist screen period 7 day 13-week double-blind treatment period . The screening period include 4 day tolerability testing , necessary . In double-blind treatment period , patient randomly assign 1 4 treatment group ( 3 fix dos paliperidone palmitate placebo ) receive 4 i.m . injection paliperidone palmitate placebo Days 1 , 8 , 36 , 64 . The study , include screen period , last approximately 14 week . Efficacy assess throughout study use Positive Negative Symptom Scale Schizophrenia ( PANSS ) , Clinical Global Impression-Severity ( CGI-S ) , Personal Social Performance Scale ( PSP ) . Safety evaluate throughout study monitor adverse event , extrapyramidal symptom ( EPS ) rating scale score , clinical laboratory test result ; vital sign body weight measurement ; electrocardiogram ( ECGs ) ; physical examination finding . In addition , tolerability injection assess . ER OROS paliperidone 3 mg/day 4 day . Injections ( i.m . ) paliperidone palmitate ( 25 , 50 , 100 mg eq . ) give Days 1 , 8 , 36 , 64 .</detailed_description>
	<mesh_term>Schizophrenia</mesh_term>
	<mesh_term>Paliperidone Palmitate</mesh_term>
	<criteria>Patients meet diagnostic criterion schizophrenia accord DSMIV least 1 year meet PANSS score criterion body mass index ( BMI ) &gt; 15.0 kilogram ( kg ) /meter ( ) 2 . Patients primary active DSMIV Axis I diagnosis schizophrenia decrease &gt; /=25 % PANSS score DSMIV diagnosis active substance dependence within 3 month screen evaluation ( nicotine caffeine dependence exclusionary ) history treatment resistance define failure respond 2 adequate trial different antipsychotic medication severe preexist gastrointestinal narrowing ( pathologic iatrogenic ) significant risk suicidal , homicidal violent ideation behavior current presence significant unstable medication condition treatment protocol disallow therapy clinically significant result screen laboratory ECG .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>January 2011</verification_date>
	<keyword>Schizophrenia</keyword>
	<keyword>Paliperidone palmitate</keyword>
	<keyword>R092670</keyword>
	<keyword>antipsychotic</keyword>
</DOC>